Market Research Report

A quick peek into the report

Global Neoantigen Cancer Vaccine Market

Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis - Analysis and Forecast, 2024-2031

 
Some Faq's

Frequently Asked Questions

The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031.
The top market players are Moderna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom, NantBioScience, Immunovaccine, BioLineRx, Geneos Therapeutics.
Factors driving the growth of the neoantigen cancer vaccine market are increasing global prevalence of cancer, increase in adoption of personalized medicine to tailor patient & treatment on an individual level, and significant external funding for executing research and development exercises.
Some of the main challenges restricting the growth of the neoantigen cancer vaccine market are the higher cost of personalized cancer vaccines, hurdles in clinical development and optimization process, uncertain reimbursement scenario, payer uncertainty and outcome-based pricing, and high capital requirement hampering the expansion of global reach.
The potential opportunities that are likely to boost the growth of the neoantigen cancer vaccine market are treatment gaps, reduced turnaround time and cost, partnerships and collaboration between various healthcare stakeholders, and data analytics.
Similar Product

You may also like

Published Year: 2019

Global Hematology Testing Market: Focus on Product Type, End-User, 11 Countries’ Data, and Competi

The global hematology testing market was valued to be $4.54 billion in 2018 and is anticipated ...